Every effort has been made to ensure this guide’s accuracy. If an actual or apparent conflict between this document and an agency rule arises, the agency rules apply.
About this guide*

This publication takes effect October 1, 2017, and supersedes earlier guides to this program.

HCA is committed to providing equal access to our services. If you need an accommodation or require documents in another format, please call 1-800-562-3022. People who have hearing or speech disabilities, please call 711 for relay services.

Washington Apple Health means the public health insurance programs for eligible Washington residents. Washington Apple Health is the name used in Washington State for Medicaid, the children's health insurance program (CHIP), and state-only funded health care programs. Washington Apple Health is administered by the Washington State Health Care Authority.

What has changed?

<table>
<thead>
<tr>
<th>Subject</th>
<th>Change</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fully Integrated Managed Care (FIMC)</strong></td>
<td>Effective January 1, 2018, the agency is implementing a <strong>second FIMC region</strong>, the North Central (NC) region, which includes Douglas, Chelan, and Grant Counties. The agency has updated and consolidated the FIMC information in this guide and provided several hyperlinks to the agency’s <a href="#">Managed Care web page</a>, the agency’s <a href="#">Integrated physical and behavioral health care web page</a>, and the agency’s <a href="#">Regional resource web page</a>.</td>
<td>Notification of new region moving to FIMC</td>
</tr>
</tbody>
</table>

* This publication is a billing instruction.
How can I get agency provider documents?

To download and print agency provider notices and billing guides, go to the agency’s Provider Publications website.

Copyright disclosure

Current Procedural Terminology (CPT) copyright 2016 American Medical Association (AMA). All rights reserved. CPT is a registered trademark of the American Medical Association.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
Table of Contents

About this guide ........................................................................................................................... 2
What has changed? ..................................................................................................................... 2
How can I get agency provider documents? ................................................................. 3

Definitions ................................................................................................................................... 6

About the Program ...................................................................................................................... 8
What is the purpose of the Kidney Center Services program? ................................................ 8
What are the provider requirements? ....................................................................................... 8
Is it required that clients be notified of their rights (Advance Directives)? ......................... 9

Client Eligibility ...................................................................................................................... 10
How can I verify a patient’s eligibility? ................................................................................... 10
Are clients enrolled in an agency-contracted managed care organization (MCO) eligible? ................................................................. 11
Effective July 1, 2017, not all Apple Health clients were enrolled in a
BHO/FIMC/BHSO ................................................................................................................... 11
Effective January 1, 2017, some fee-for-service clients who have other primary health
insurance were enrolled into managed care ........................................................................... 12
Effective April 1, 2016, important changes to Apple Health ................................................... 12
  New MCO enrollment policy – earlier enrollment .............................................................. 12
  How does this policy affect providers? ............................................................................. 13
  Behavioral Health Organization (BHO) ........................................................................... 13
  Fully Integrated Managed Care (FIMC) ........................................................................ 14
  FIMC Regions................................................................................................................ 15
  Apple Health Core Connections (AHCC) ...................................................................... 15
  AHCC complex mental health and substance use disorder services .............................. 15
  Contact Information for Southwest Washington ......................................................... 16

Coverage .................................................................................................................................... 17
What is not covered? ................................................................................................................. 17
What is covered? ...................................................................................................................... 17
What types of service are covered by other agency programs? ............................................. 18
What HCPCS codes for blood processing are used in outpatient blood transfusions? .......... 19
  Revenue codes .............................................................................................................. 20

Authorization ........................................................................................................................... 26
What is expedited prior authorization (EPA)? ....................................................................... 26
  EPA guidelines ............................................................................................................ 26
  EPA Criteria Coding List ............................................................................................ 27

Alert! This Table of Contents is automated. Click on a page number to go directly to the page.
Kidney Center Services

What is a limitation extension (LE)? .................................................................28
Is prior authorization (PA) required for an LE? ................................................28
How do I get LE authorization? .......................................................................28
What is written or fax authorization? ...............................................................28
How is written or fax authorization requested? ..............................................28

Payment ..............................................................................................................29
How does the agency pay for kidney center services? ......................................29
What is included in the composite rate? ..........................................................30
How many dialysis sessions are included in the composite rate payment? ....30
Can services and supplies that are not included in the composite rate be billed
separately? ........................................................................................................31
What laboratory services are included in the composite rate? ......................32
What does the agency pay free-standing kidney centers for? .........................34
When does the agency pay for Epoetin Alpha (EPO) therapy? ......................35
Where is the fee schedule? ...............................................................................35

Billing ..................................................................................................................36
What are the general billing requirements? .....................................................36
Definitions

This section defines terms and abbreviations, including acronyms, used in this billing guide. Refer to Chapter 182-500 WAC for a complete list of definitions for Washington Apple Health.

** Affiliate - A facility, hospital, unit, business, or person having an agreement with a kidney center to provide specified services to ESRD patients. **

** Agreement - A written document executed between an ESRD facility and another facility in which the other facility agrees to assume responsibility for furnishing specified services to patients and for obtaining payment for those services. **

** Back-Up Dialysis - Dialysis given to patients under special circumstances in a situation other than the patients’ usual dialysis environment. Examples are:**

- Dialysis of a home dialysis patient in a dialysis facility when patient’s equipment fails.
- In-hospital dialysis when the patient’s illness requires more comprehensive care on an inpatient basis.
- Pre- and post-operative dialysis provided to transplant patients.

** Composite Rate - This refers to a payment method in which all standard equipment, supplies, and services are calculated into a blended rate. All in-facility dialysis treatments and all home dialysis treatments are billed under the composite rate system. **

**Continuous Ambulatory Peritoneal Dialysis (CAPD) - A type of dialysis where the patient’s peritoneal membrane is used as the dialyzer. The patient dialyzes at home, using special supplies, but without the need for a machine (see Peritoneal Dialysis). **

**Continuous Cycling Peritoneal Dialysis (CCPD) - A type of peritoneal dialysis where the patient dialyzes at home and utilizes an automated peritoneal cycler for delivering dialysis. **

** Dialysate - An electrolyte solution, containing elements such as potassium, sodium-chloride, etc., surrounding the membrane or fibers and allowing exchange of substances with the patient’s blood in the dialyzer. **

** Dialysis - A process by which dissolved substances are removed from a patient’s body by diffusion from one fluid compartment to another across a semipermeable membrane. **

** Dialysis Session - The period of time beginning when the patient arrives at the facility and ending when the patient departs from the facility. In the case of home dialysis, the time period beginning when the patient prepares for dialysis and ending when the patient is disconnected from the machine. **
**Dialyzer** - Synthetic porous membrane or fibers, contained in a supporting structure, through which blood flows for the purpose of eliminating harmful substances and replacing with useful ones.

**End-Stage Renal Disease (ESRD)** - The stage of renal impairment that is irreversible and permanent, and requires dialysis or kidney transplantation to ameliorate uremic symptoms and maintain life.

**Epoetin Alpha (EPO)** - An injectable drug that is a biologically engineered protein that stimulates the bone marrow to make new red blood cells.

**Free-Standing Kidney Center** - A limited care facility, not operated by a hospital, certified by the federal government to provide ESRD services.

**Hemodialysis** - A method of dialysis in which blood from a patient’s body is circulated through an external device or machine and then returned to the patient’s bloodstream. Hemodialysis is usually done in a kidney center or facility. It can be done at home with a trained helper.

**Home Dialysis** - Refers to any dialysis performed at home.

**Home Dialysis Helper** - A person trained to assist the client in home dialysis.

**In-Facility Dialysis** - For the purpose of this guide only, in-facility dialysis is dialysis of any type performed on the premises of the kidney center or other free-standing ESRD facility.

**Intermittent Peritoneal Dialysis (IPD)** - A type of peritoneal dialysis in which dialysis solution is infused into the peritoneal cavity, allowed to remain there for a period of time, and then drained out. IPD is usually done in a kidney center or facility. It can be done at home with a trained home dialysis helper.

**Kidney Center** - A facility as defined and certified by the federal government to:

- Provide ESRD services.
- Provide the services specified in this chapter.
- Promote and encourage home dialysis for a client when medically indicated.

**Maintenance Dialysis** - The usual periodic dialysis treatments given to a patient who has ESRD.

**Peritoneal Dialysis** - A procedure that introduces dialysate into the abdominal cavity to remove waste products through the peritoneum. Three forms of peritoneal dialysis are: Continuous Ambulatory Peritoneal Dialysis, Continuous Cycling Peritoneal Dialysis, and Intermittent Peritoneal Dialysis.

**Self-Dialysis Unit** - A unit in a free-standing kidney center where dialysis is performed by an ESRD client who has completed training in self-dialysis.
About the Program

(WAC 182-540-101)

What is the purpose of the Kidney Center Services program?

The purpose of the Kidney Center Services program is to assist low-income residents with the cost of treatment for end-stage renal disease (ESRD).

What are the provider requirements?

(WAC 182-540-120)

To receive payment from the agency for providing care to eligible clients, a kidney center must:

- Be a Medicare-certified ESRD facility
- Have a signed Core Provider Agreement (CPA) with the agency and meet the requirements in WAC 182-502 Administration of Medical Programs-Providers. Visit the Provider Enrollment website for further information on the CPA.
- Provide only those services that are within the scope of their provider's license
- Provide services, either directly or through an affiliate, all physical facilities, professional consultation, personal instructions, medical treatment, care, and all supplies necessary for carrying out a medically-sound ESRD treatment program. Services include:
  - Dialysis for clients with ESRD
  - Kidney transplant treatment for ESRD clients when medically indicated
  - Treatment for conditions directly related to ESRD
  - Training and supervision of supporting personnel and clients for home dialysis, medical care, and treatment
  - Supplies and equipment for home dialysis
Is it required that clients be notified of their rights (Advance Directives)?

(42 CFR, Part 489, Subpart I)

Yes. All Medicare/Medicaid-certified hospitals, nursing facilities, home health agencies, personal care service agencies, hospices, and managed health care organizations are federally mandated to give all adult clients written information about their rights, under state law, to make their own health care decisions.

Clients have the right to:

- Accept or refuse medical treatment
- Make decisions concerning their own medical care
- Formulate an advance directive, such as a living will or durable power of attorney, for their health care
Client Eligibility

(WAC 182-540-110(1))

How can I verify a patient’s eligibility?

Providers must verify that a patient has Washington Apple Health coverage for the date of service, and that the client’s benefit package covers the applicable service. This helps prevent delivering a service the agency will not pay for.

Verifying eligibility is a two-step process:

Step 1. **Verify the patient’s eligibility for Washington Apple Health.** For detailed instructions on verifying a patient’s eligibility for Washington Apple Health, see the Client Eligibility, Benefit Packages, and Coverage Limits section in the agency’s current ProviderOne Billing and Resource Guide.

If the patient is eligible for Washington Apple Health, proceed to **Step 2**. If the patient is **not** eligible, see the note box below.

Step 2. **Verify service coverage under the Washington Apple Health client’s benefit package.** To determine if the requested service is a covered benefit under the Washington Apple Health client’s benefit package, see the agency’s Program Benefit Packages and Scope of Services web page.

**Note:** Patients who wish to apply for Washington Apple Health can do so in one of the following ways:

1. By visiting the Washington Healthplanfinder’s website at: www.wahealthplanfinder.org
2. By calling the Customer Support Center toll-free at: 855-WAFINDER (855-923-4633) or 855-627-9604 (TTY)
3. By mailing the application to: Washington Healthplanfinder PO Box 946 Olympia, WA 98507

In-person application assistance is also available. To get information about in-person application assistance available in their area, people may visit www.wahealthplanfinder.org or call the Customer Support Center.
Are clients enrolled in an agency-contracted managed care organization (MCO) eligible? (WAC 182-540-110(2))

Yes. Most Medicaid-eligible clients are enrolled in one of the agency’s contracted managed care organizations (MCOs). For these clients, managed care enrollment will be displayed on the client benefit inquiry screen in ProviderOne.

All medical services covered under an agency-contracted MCO must be obtained by the client through designated facilities or providers. The MCO is responsible for:

- Payment of covered services
- Payment of services referred by a provider participating with the plan to an outside provider

The client’s plan covers hemodialysis or other appropriate procedures to treat renal failure, including equipment needed in the course of treatment.

**Note:** A client’s enrollment can change monthly. Providers who are not contracted with the MCO must receive approval from both the MCO and the client’s primary care provider (PCP) prior to serving a managed care client.

Send claims to the client’s MCO for payment. Call the client’s MCO to discuss payment prior to providing the service. Providers may bill clients only in very limited situations as described in WAC 182-502-0160

**Note:** To prevent billing denials, check the client’s eligibility prior to scheduling services and at the time of the service, and make sure proper authorization or referral is obtained from the agency-contracted MCO, if appropriate. See the agency’s ProviderOne Billing and Resource Guide for instructions on how to verify a client’s eligibility.

Effective July 1, 2017, not all Apple Health clients were enrolled in a BHO/FIMC/BHSO

On July 1, 2017, some Apple Health clients were not enrolled in a BHO/FIMC/BHSO program. For these clients, substance use disorder (SUD) services are covered under the fee-for-service (FFS) program.
Effective January 1, 2017, some fee-for-service clients who have other primary health insurance were enrolled into managed care

On January 1, 2017, the agency enrolled some fee-for-service Apple Health clients who have other primary health insurance into an agency-contracted managed care organization (MCO).

This change did not affect all fee-for-service Apple Health clients who have other primary health insurance. The agency continues to cover some clients under the fee-for-service Apple Health program, such as dual-eligible clients whose primary insurance is Medicare.

For additional information, see the agency’s Managed Care web page, under Providers and Billers.

Effective April 1, 2016, important changes to Apple Health

These changes are important to all providers because they may affect who will pay for services.

Providers serving any Apple Health client should always check eligibility and confirm plan enrollment by asking to see the client’s Services Card and/or using the ProviderOne Managed Care Benefit Information Inquiry functionality (HIPAA transaction 270). The response (HIPAA transaction 271) will provide the current managed care organization (MCO), fee-for-service, and Behavioral Health Organization (BHO) information. See the agency’s Regional Resources web page.

New MCO enrollment policy – earlier enrollment

Beginning April 1, 2016, Washington Apple Health (Medicaid) implemented a new managed care enrollment policy placing clients into an agency-contracted MCO the same month they are determined eligible for managed care as a new or renewing client. This policy eliminates a person being placed temporarily in fee-for-service while they are waiting to be enrolled in an MCO or reconnected with a prior MCO.

New clients are those initially applying for benefits or those with changes in their existing eligibility program that consequently make them eligible for Apple Health Managed Care.

Renewing clients are those who have been enrolled with an MCO but have had a break in enrollment and have subsequently renewed their eligibility.
Clients currently in fee-for-service or currently enrolled in an MCO are not affected by this change. Clients in fee-for-service who have a change in the program they are eligible for may be enrolled into Apple Health Managed Care depending on the program. In those cases, this enrollment policy will apply.

How does this policy affect providers?

- Providers must check eligibility and know when a client is enrolled and with which MCO. For help with enrolling, clients can refer to the Washington Healthplanfinder’s Get Help Enrolling page.

- MCOs have retroactive authorization and notification policies in place. The provider must know the MCO’s requirements and be compliant with the MCO’s new policies.

Behavioral Health Organization (BHO)

The Department of Social and Health Services (DSHS) manages the contracts for behavioral health (mental health and substance use disorder (SUD)) services for nine of the Regional Service Areas (RSA) in the state, excluding Clark and Skamania counties in the Southwest Washington (SW WA) Region. BHOs replaced the Regional Support Networks (RSNs). Inpatient mental health services continue to be provided as described in the inpatient section of the Mental Health Services Billing Guide. BHOs use the Access to Care Standards (ACS) for mental health conditions and American Society of Addiction Medicine (ASAM) criteria for SUD conditions to determine client’s appropriateness for this level of care.
Fully Integrated Managed Care (FIMC)

For clients who live in a fully integrated managed care (FIMC) region, all physical health services, mental health services, and drug and alcohol treatment are covered and coordinated by the client’s agency-contracted managed care organization (MCO). The Behavioral Health Organization (BHO) will not provide behavioral health services in these counties.

Clients living in an FIMC region will enroll with an MCO of their choice that is available in that region. If the client does not choose an MCO, the client will be automatically enrolled into one of the available MCOs, unless the client is American Indian/Alaska Native (AI/AN). Clients currently enrolled in one of the available MCOs in their region may keep their enrollment when the behavioral health services are added.

**Effective July 1, 2017, American Indian/Alaska Native (AI/AN) clients living in an FIMC region of Washington must choose to enroll in one of the agency-contracted MCOs available in that region; or they may choose to receive all these services through Apple Health fee-for-service (FFS). If they do not choose an MCO, they will be automatically enrolled into Apple Health FFS for all their health care services, including comprehensive behavior health services. For more information about the services available under the FFS program, the agency’s [Mental Health Services Billing Guide](#) and the [Substance Use Disorder Billing Guide](#).**

For full details on FIMC, including which clients residing in an FIMC region are not enrolled with an MCO and information on complex behavioral health services for foster children in an FIMC region, see the agency’s [Managed Care web page](#), the agency’s [Integrated physical and behavioral health care web page](#), and the agency’s [Regional resource web page](#).
FIMC Regions

North Central Region (NC) – Douglas, Chelan and Grant Counties

Effective January 1, 2018, the agency will implement the second FIMC region known as the NC region which includes Douglas, Chelan, and Grant Counties. Clients eligible for managed care enrollment will choose to enroll in an available MCO in their region. Specific details, including information about mental health crisis services, can be found on the agency’s Managed Care web page, the agency’s Integrated physical and behavioral health care web page, and the agency’s Regional resource web page.

Southwest Washington Region (SW WA) – Clark and Skamania Counties

Effective April 1, 2016, the agency implemented the first FIMC region known as the SW WA region which includes Clark and Skamania Counties. Clients eligible for managed care enrollment choose to enroll in one of two available MCOs in this region: Community Health Plan of Washington (CHPW) or Molina Healthcare of Washington (MHW).

Apple Health Core Connections (AHCC)

Coordinated Care of Washington (CCW) will provide all physical health care (medical) benefits, lower-intensity outpatient mental health benefits, and care coordination for all Washington State foster care enrollees. These clients include:

- Children and youth under the age of 21 who are in foster care
- Children and youth under the age of 21 who are receiving adoption support
- Young adults age 18 to 26 years old who age out of foster care on or after their 18th birthday

American Indian/Alaska Native (AI/AN) children will not be auto-enrolled, but may opt into CCW. All other eligible clients will be automatically enrolled.

AHCC complex mental health and substance use disorder services

AHCC clients who live in Skamania or Clark County receive complex behavioral health benefits through the Behavioral Health Services Only (BHSO) program in the SW WA region. These clients will choose between CHPW or MHW for behavioral health services, or they will be auto-enrolled into one of the two plans. CHPW and MHW will use the BHO Access to Care Standards to support determining appropriate level of care, and whether the services should be provided by the BHSO program or CCW.

AHCC clients who live outside Skamania or Clark County will receive complex mental health and substance use disorder services from the BHO and managed by DSHS.
Contact Information for Southwest Washington

Beginning on April 1, 2016, there is not an RSN/BHO in Clark and Skamania counties. Providers and clients must call the agency-contracted MCO for questions, or call Beacon Health Options for questions related to a person who is not eligible for or enrolled in Medicaid.

If a provider does not know which MCO a client is enrolled in, this information can located by looking up the patient assignment in ProviderOne.

To contact Molina, Community Health Plan of Washington, or Beacon Health Options, please call:

<table>
<thead>
<tr>
<th>Provider</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molina Healthcare of Washington, Inc.</td>
<td>1-800-869-7165</td>
</tr>
<tr>
<td>Community Health Plan of Washington</td>
<td>1-866-418-1009</td>
</tr>
<tr>
<td>Beacon Health Options</td>
<td>1-855-228-6502</td>
</tr>
</tbody>
</table>
Kidney Center Services

Coverage

What is not covered?
(WAC 182-540-140)

The agency does not cover services provided in a kidney center such as:

- Blood and blood products (see WAC 182-540-190)
- Personal care items such as slippers, toothbrushes, etc.
- Additional staff time or personnel costs. Staff time is paid through the composite rate. **Exception:** Staff time for home dialysis helpers is the only personnel cost paid outside the composite rate (see WAC 182-540-160).

The agency or its designee reviews all initial requests for noncovered services based on WAC 182-501-0160.

What is covered?
(WAC 182-540-130)

- The agency covers and pays for only the blood bank service charge for processing blood and blood products (see WAC 182-550-6500).

- The agency covers services including all of the following:
  - In-facility dialysis
  - Home dialysis
  - Self-dialysis training
  - Home dialysis helpers
  - Dialysis supplies
  - Diagnostic lab work
  - Treatment for anemia
  - Intravenous drugs

**Note:** Home dialysis helpers may assist a client living in the client's home or in a skilled nursing facility (when the skilled nursing facility is their home) with home dialysis.

- Covered services are subject to the restrictions and limitations in this guide and applicable WAC as specified by the agency. Providers must obtain a limitation extension.
(LE) before providing services that exceed specified limits in quantity, frequency, or duration. See Authorization for specifics on the LE process.

What types of service are covered by other agency programs?
(WAC 182-540-150(3-4))

Other agency programs cover the following services:

- **Take Home Drugs** – Take home drugs (outpatient prescription drugs not being administered in the provider’s office) must be supplied and billed by a pharmacy, subject to pharmacy pricing methodology outlined in the agency’s current Prescription Drug Program Billing guide.

- **Medical Nutrition** – Only pharmacies or other medical nutrition providers may supply supplemental food products. Bill for these services using the agency’s current Enteral Nutrition Billing guide.
What HCPCS codes for blood processing are used in outpatient blood transfusions?

The codes listed below must be used to represent costs for:

- Blood processing and other fees assessed by nonprofit blood centers that do not charge for the blood and blood products themselves.
- Costs incurred by a center to administer its in-house blood procurement program. However, these costs must not include any staff time used to administer blood.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Short Descriptions</th>
<th>Policy/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>P9010</td>
<td>Whole blood for transfusion</td>
<td></td>
</tr>
<tr>
<td>P9011</td>
<td>Blood split unit</td>
<td></td>
</tr>
<tr>
<td>P9012</td>
<td>Cryoprecipitate each unit</td>
<td></td>
</tr>
<tr>
<td>P9016</td>
<td>RBC leukocytes reduced</td>
<td></td>
</tr>
<tr>
<td>P9017</td>
<td>Fresh frozen plasma (single donor), each unit</td>
<td></td>
</tr>
<tr>
<td>P9019</td>
<td>Platelets, each unit</td>
<td></td>
</tr>
<tr>
<td>P9020</td>
<td>Plasma 1 donor frz w/in 8 hr</td>
<td></td>
</tr>
<tr>
<td>P9021</td>
<td>Red blood cells unit</td>
<td></td>
</tr>
<tr>
<td>P9022</td>
<td>Washed red blood cells unit</td>
<td></td>
</tr>
<tr>
<td>P9023</td>
<td>Frozen plasma, pooled, sd</td>
<td></td>
</tr>
<tr>
<td>P9031</td>
<td>Platelets leukocytes reduced</td>
<td></td>
</tr>
<tr>
<td>P9032</td>
<td>Platelets, irradiated</td>
<td></td>
</tr>
<tr>
<td>P9033</td>
<td>Platelets leukoreduced irrad</td>
<td></td>
</tr>
<tr>
<td>P9034</td>
<td>Platelets, pheresis</td>
<td></td>
</tr>
<tr>
<td>P9035</td>
<td>Platelet pheres leukoreduced</td>
<td></td>
</tr>
<tr>
<td>P9036</td>
<td>Platelet pheresis irradiated</td>
<td></td>
</tr>
<tr>
<td>P9037</td>
<td>Plate pheres leukoredu irrad</td>
<td></td>
</tr>
<tr>
<td>P9038</td>
<td>RBC irradiated</td>
<td></td>
</tr>
<tr>
<td>P9039</td>
<td>RBC deglycerolized</td>
<td></td>
</tr>
<tr>
<td>P9040</td>
<td>RBC leukoreduced irradiated</td>
<td></td>
</tr>
<tr>
<td>P9041</td>
<td>Albumin (human), 5%, 50ml</td>
<td></td>
</tr>
<tr>
<td>P9043</td>
<td>Plasma protein fract,5%,50ml</td>
<td></td>
</tr>
<tr>
<td>P9044</td>
<td>Cryoprecipitaterducedplasma</td>
<td></td>
</tr>
<tr>
<td>P9045</td>
<td>Albumin (human), 5%, 250 ml</td>
<td></td>
</tr>
<tr>
<td>P9046</td>
<td>Albumin (human), 25%, 20 ml</td>
<td></td>
</tr>
<tr>
<td>P9047</td>
<td>Albumin (human), 25%, 50ml</td>
<td></td>
</tr>
<tr>
<td>P9048</td>
<td>Plasmaprotein fract,5%,250ml</td>
<td></td>
</tr>
<tr>
<td>P9050</td>
<td>Granulocytes, pheresis unit</td>
<td></td>
</tr>
<tr>
<td>P9054</td>
<td>Blood, l/r, froz/degly/wash</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Short Descriptions</th>
<th>Policy/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>P9055</td>
<td>Plt, aph/pher, l/r, cmv-neg</td>
<td></td>
</tr>
<tr>
<td>P9056</td>
<td>Blood, l/r, irradiated</td>
<td></td>
</tr>
<tr>
<td>P9057</td>
<td>RBC, frz/deg/wsh, l/r, irrad</td>
<td></td>
</tr>
<tr>
<td>P9058</td>
<td>RBC, l/r, cmv-neg, irrad</td>
<td></td>
</tr>
<tr>
<td>P9059</td>
<td>Plasma, frz between 8-24 hour</td>
<td></td>
</tr>
<tr>
<td>P9060</td>
<td>Fr frz plasma donor retested</td>
<td></td>
</tr>
</tbody>
</table>

### Revenue codes

<table>
<thead>
<tr>
<th>Revenue Code</th>
<th>HCPCS Code</th>
<th>Short Description</th>
<th>Policy/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>NOTE:</strong> In order to receive payment for <strong>revenue code 0270</strong>, the HCPCS code of the specific supply given must be indicated in the <strong>Procedure Code</strong> field of the institutional claim. Payment is limited to <strong>those supplies listed below</strong>.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0270</td>
<td>A4657</td>
<td>Syringe w/wo needle</td>
<td></td>
</tr>
<tr>
<td>0270</td>
<td>A4750</td>
<td>Art or venous blood tubing</td>
<td></td>
</tr>
<tr>
<td>0270</td>
<td>A4913</td>
<td>Misc dialysis supplies noc (use for IV tubing, pump)</td>
<td></td>
</tr>
</tbody>
</table>

**Medical/Surgical Supplies and Devices** *(Requires specific identification using a HCPCS code)*

### Laboratory

**Note:** In order to receive payment for **revenue code 0300**, the following modifiers must be used:

- *CB* - Service ordered by a renal dialysis facility (RDF) physician as part of the ESRD beneficiary's dialysis benefit, is not part of the composite rate, and is separately reimbursable.

- **CE** - AMCC test has been ordered by an ESRD facility or MCP physician that is a composite rate test, but is beyond the normal frequency covered under the rate and is separately reimbursable based on medical necessity.

<table>
<thead>
<tr>
<th>Revenue Code</th>
<th>Short Description</th>
<th>Policy/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0300</td>
<td>Laboratory, General Classification</td>
<td>*Not part of the composite rate or *<em>Beyond normal frequency covered</em></td>
</tr>
<tr>
<td>0303</td>
<td>Laboratory, renal patient (home)</td>
<td></td>
</tr>
<tr>
<td>0304</td>
<td>Laboratory, non-routine dialysis</td>
<td></td>
</tr>
</tbody>
</table>

**Drugs**

**Note:** Providers must use the correct 11-digit National Drug Code (NDC) when billing the agency for drugs administered to eligible clients in kidney centers.
Kidney Center Services

<table>
<thead>
<tr>
<th>Revenue Code</th>
<th>HCPCS Code</th>
<th>Short Description</th>
<th>Policy/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epoetin Alpha (EPO)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Note: When billing with revenue codes 0634 and 0635, each billing unit reported on the claim form represents 100 units of EPO given.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0634</td>
<td></td>
<td>Erythropoietin (EPO) less than 10,000 units</td>
<td></td>
</tr>
<tr>
<td>0634</td>
<td>Q4081</td>
<td>Epoetin alfa, 100 units ESRD</td>
<td>100 units</td>
</tr>
<tr>
<td>0635</td>
<td></td>
<td>Erythropoietin (EPO) 10,000 or more units</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Revenue Code</th>
<th>Procedure Code</th>
<th>Short Description</th>
<th>Policy/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Drugs Requiring Specific Identification</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Note: In order to receive payment for revenue code 0636, the HCPCS code of the specific drug given must be indicated in the Procedure Code field of the institutional claim. Payment is limited to the drugs listed below.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0636</td>
<td></td>
<td>Administration of drugs</td>
<td>Bill number of units based on the description of the drug code)</td>
</tr>
<tr>
<td>0636</td>
<td>90656</td>
<td>Flu vaccine no preserv 3 &amp; &gt;</td>
<td></td>
</tr>
<tr>
<td>0636</td>
<td>90657</td>
<td>Flu vaccine 3 yrs im</td>
<td></td>
</tr>
<tr>
<td>0636</td>
<td>90658</td>
<td>Flu vaccine 3 yrs &amp; &gt; im</td>
<td></td>
</tr>
<tr>
<td>0636</td>
<td>90670</td>
<td>Pneumococcal conjugate vaccine, 13 valent, for intramuscular use</td>
<td>New code effective 1/1/16</td>
</tr>
<tr>
<td>0636</td>
<td>90673</td>
<td>Flu vaccine no preserv im</td>
<td></td>
</tr>
<tr>
<td>0636</td>
<td>90686</td>
<td>Flu vaccine 3 yrs &amp; &gt; im</td>
<td></td>
</tr>
<tr>
<td>0636</td>
<td>90732</td>
<td>Pneumococcal vaccine</td>
<td></td>
</tr>
<tr>
<td>0636</td>
<td>90747</td>
<td>Hepb vacc ill pat 4 dose im</td>
<td>40 mcg</td>
</tr>
<tr>
<td>0636</td>
<td>J0280</td>
<td>Aminophyllin 250 MG inj</td>
<td>250 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0285</td>
<td>Amphotericin B</td>
<td>50 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0290</td>
<td>Ampicillin 500 MG inj</td>
<td>500 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0295</td>
<td>Ampicillin sodium per 1.5 gm</td>
<td>1.5 g</td>
</tr>
<tr>
<td>0636</td>
<td>J0360</td>
<td>Hydralazine hcl injection</td>
<td>20 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0610</td>
<td>Calcium gluconate injection</td>
<td>10 ml</td>
</tr>
<tr>
<td>0636</td>
<td>J0630</td>
<td>Calcitonin salmon injection</td>
<td>400 u</td>
</tr>
<tr>
<td>0636</td>
<td>J0636</td>
<td>Inj calcitriol per 0.1 mcg</td>
<td>0.1 mcg</td>
</tr>
<tr>
<td>0636</td>
<td>J0640</td>
<td>Leucovorin calcium injection</td>
<td>50 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0690</td>
<td>Cefazolin sodium injection</td>
<td>500 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0692</td>
<td>Cefepime HCl for injection</td>
<td>500 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0694</td>
<td>Cefoxitin sodium injection</td>
<td>1 gm</td>
</tr>
<tr>
<td>0636</td>
<td>J0696</td>
<td>Ceftriaxone sodium injection</td>
<td>250 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0697</td>
<td>Sterile cefuroxime injection</td>
<td>750 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0698</td>
<td>Cefotaxime sodium injection</td>
<td>per g</td>
</tr>
<tr>
<td>0636</td>
<td>J0702</td>
<td>Betamethasone acet&amp;sod phosp</td>
<td>3 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Revenue Code</th>
<th>Procedure Code</th>
<th>Short Description</th>
<th>Policy/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0636</td>
<td>J0710</td>
<td>Cephapirin sodium injection</td>
<td></td>
</tr>
<tr>
<td>0636</td>
<td>J0713</td>
<td>Inj ceftazidime per 500 mg</td>
<td>500 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0743</td>
<td>Cilastatin sodium injection</td>
<td>per 250 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0780</td>
<td>Prochlorperazine injection</td>
<td>10 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0878</td>
<td>Daptomycin injection</td>
<td>1 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0882</td>
<td>Darbepoetin alfa, esrd use</td>
<td>1 mcg</td>
</tr>
<tr>
<td>0636</td>
<td>J0887</td>
<td>Epoetin beta injection</td>
<td>1 mcg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PA required</td>
</tr>
<tr>
<td>0636</td>
<td>J0895</td>
<td>Deferoxamine mesylate inj</td>
<td>500 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J0970</td>
<td>Estradiol valerate injection</td>
<td>40 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1094</td>
<td>Inj dexamethasone acetate</td>
<td>1 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1160</td>
<td>Digoxin injection</td>
<td>0.5 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1165</td>
<td>Phenytoin sodium injection</td>
<td>50 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1170</td>
<td>Hydromorphone injection</td>
<td>4 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1200</td>
<td>Diphenhydramine hcl injection</td>
<td>50 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1240</td>
<td>Dimenhydrinate injection</td>
<td>50 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1270</td>
<td>Injection, doxercalciferol</td>
<td>1 mcg</td>
</tr>
<tr>
<td>0636</td>
<td>J1335</td>
<td>Ertapenem injection</td>
<td>500 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1580</td>
<td>Garamycin gentamicin inj</td>
<td>80 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1630</td>
<td>Haloperidol injection</td>
<td>5 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1631</td>
<td>Haloperidol decanoate inj</td>
<td>50 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1645</td>
<td>Dalteparin sodium</td>
<td>2500 IU</td>
</tr>
<tr>
<td>0636</td>
<td>J1720</td>
<td>Hydrocortisone sodium succ i</td>
<td>100 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1750</td>
<td>Inj iron dextran</td>
<td>50 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1756</td>
<td>Iron sucrose injection</td>
<td>1 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1790</td>
<td>Droperidol injection</td>
<td>5 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1800</td>
<td>Propranolol injection</td>
<td>1 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1840</td>
<td>Kanamycin sulfate 500 MG inj</td>
<td>500 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1885</td>
<td>Ketorolac tromethamine inj</td>
<td>15 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1890</td>
<td>Cephalothin sodium injection</td>
<td>1 gm</td>
</tr>
<tr>
<td>0636</td>
<td>J1940</td>
<td>Furosemide injection</td>
<td>20 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1955</td>
<td>Inj levocarnitine per 1 gm</td>
<td>1 gm</td>
</tr>
<tr>
<td>0636</td>
<td>J1956</td>
<td>Levofoxacin injection</td>
<td>250 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J1990</td>
<td>Chlordiazepoxide injection</td>
<td>100 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2001</td>
<td>Lidocaine injection</td>
<td>10 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2060</td>
<td>Lorazepam injection</td>
<td>2 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2150</td>
<td>Mannitol injection</td>
<td>50 ml</td>
</tr>
<tr>
<td>0636</td>
<td>J2175</td>
<td>Meperidine hydrochl /100 MG</td>
<td>100 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2185</td>
<td>Meropenem</td>
<td>100 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2270</td>
<td>Morphine sulfate injection</td>
<td>10 mg</td>
</tr>
<tr>
<td>Revenue Code</td>
<td>Procedure Code</td>
<td>Short Description</td>
<td>Policy/Comments</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------</td>
<td>-------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>0636</td>
<td>J2320</td>
<td>Nandrolone decanoate 50 MG</td>
<td>50 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2501</td>
<td>Paricalcitol</td>
<td>1 mcg</td>
</tr>
<tr>
<td>0636</td>
<td>J2510</td>
<td>Penicillin g procaine inj</td>
<td>600,000u</td>
</tr>
<tr>
<td>0636</td>
<td>J2540</td>
<td>Penicillin g potassium inj</td>
<td>600,000u</td>
</tr>
<tr>
<td>0636</td>
<td>J2550</td>
<td>Promethazine hcl injection</td>
<td>50 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2560</td>
<td>Phenobarbital sodium inj</td>
<td>120 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2690</td>
<td>Procainamide hcl injection</td>
<td>1 gm</td>
</tr>
<tr>
<td>0636</td>
<td>J2700</td>
<td>Oxacillin sodium injection</td>
<td>250 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2720</td>
<td>Inj protamine sulfate/10 MG</td>
<td>10 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2765</td>
<td>Metoclopramide hcl injection</td>
<td>10 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2800</td>
<td>Methocarbamol injection</td>
<td>10 ml</td>
</tr>
<tr>
<td>0636</td>
<td>J2916</td>
<td>Na ferric gluconate complex</td>
<td>12.5 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2920</td>
<td>Methylprednisolone injection</td>
<td>40 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2930</td>
<td>Methylprednisolone injection</td>
<td>125 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J2995</td>
<td>Inj streptokinase /250000 IU</td>
<td>250,000 IU</td>
</tr>
<tr>
<td>0636</td>
<td>J2997</td>
<td>Alteplase recombinant</td>
<td>1 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J3000</td>
<td>Streptomycin injection</td>
<td>1 gm</td>
</tr>
<tr>
<td>0636</td>
<td>J3010</td>
<td>Fentanyl citrate injection</td>
<td>0.1 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J3070</td>
<td>Pentazocine injection</td>
<td>30 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J3230</td>
<td>Chlorpromazine hcl injection</td>
<td>50 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J3250</td>
<td>Trimethobenzamide hcl inj</td>
<td>200 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J3260</td>
<td>Tobramycin sulfate injection</td>
<td>80 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J3280</td>
<td>Thiethylperazine maleate inj</td>
<td>10 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J3301</td>
<td>Triamcinolone acet inj NOS</td>
<td>10 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J3360</td>
<td>Diazepam injection</td>
<td>5 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J3364</td>
<td>Urokinase 5000 IU injection</td>
<td>5,000 IU vial</td>
</tr>
<tr>
<td>0636</td>
<td>J3365</td>
<td>Urokinase 250,000 IU inj</td>
<td>250,000 IU vial</td>
</tr>
<tr>
<td>0636</td>
<td>J3370</td>
<td>Vancomycin hcl injection</td>
<td>500 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J3410</td>
<td>Hydroxyzine hcl injection</td>
<td>25 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J3420</td>
<td>Vitamin b12 injection</td>
<td>1,000 mcg</td>
</tr>
<tr>
<td>0636</td>
<td>J3430</td>
<td>Vitamin k phytonadione inj</td>
<td>1mg</td>
</tr>
<tr>
<td>0636</td>
<td>J7500</td>
<td>Azathioprine oral 50mg</td>
<td>50 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J7502</td>
<td>Cyclosporine oral 100 mg</td>
<td>100 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J7504</td>
<td>Lymphocyte immune globulin, antithymocyte globulin, equine, injection</td>
<td>250 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Revenue Code</th>
<th>Procedure Code</th>
<th>Short Description</th>
<th>Policy/ Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0636</td>
<td>J7507</td>
<td>Tacrolimus oral per 1 MG</td>
<td>per 1 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J7508</td>
<td>Tacrolimus ex rel oral 0.1mg</td>
<td>0.1 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J7512</td>
<td>Prednisone, immediate release or delayed release, oral</td>
<td>1 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J7515</td>
<td>Cyclosporine oral 25 mg</td>
<td>25 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J7517</td>
<td>Mycophenolate mofetil oral</td>
<td>250 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J7518</td>
<td>Mycophenolic acid</td>
<td>180 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J7520</td>
<td>Sirolimus, oral</td>
<td>1 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J7527</td>
<td>Oral everolimus</td>
<td>0.25 mg</td>
</tr>
<tr>
<td>0636</td>
<td>J3490</td>
<td>Drugs unclassified injection</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** The National Drug Code (NDC) number and dosage given to the client must be included in the *Claim Note* section of the claim when billing unlisted drug HCPCS code J3490.

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Short Description</th>
<th>Policy/ Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2037</td>
<td>Fluvirin vacc, 3 yrs &amp; &gt;, im</td>
<td></td>
</tr>
<tr>
<td>Q2038</td>
<td>Fluzone vacc, 3 yrs &amp; &gt;, im</td>
<td></td>
</tr>
</tbody>
</table>

**EKG/ECG (Electrocardiogram) – Technical Portion Only**

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Short Description</th>
<th>Policy/ Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0730</td>
<td>General classification</td>
<td></td>
</tr>
<tr>
<td>93005</td>
<td>Electrocardiogram tracing</td>
<td></td>
</tr>
</tbody>
</table>

**Hemodialysis – Outpatient or Home**

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Short Description</th>
<th>Policy/ Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0821</td>
<td>Hemodialysis/composite rate.</td>
<td>Limited to 14 per client, per month. <em>(Do not bill in combination with 831, 841, or 851.)</em> See EPA criteria for greater than 14 in-center hemodialysis treatments per month</td>
</tr>
<tr>
<td>0825</td>
<td>Support Services</td>
<td>(Home Helper)</td>
</tr>
</tbody>
</table>

**Intermittent Peritoneal Dialysis – Outpatient or Home**

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Short Description</th>
<th>Policy/ Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0831</td>
<td>Peritoneal dialysis/Composite Rate.</td>
<td>Limited to 14 per client, per month. <em>(Do not bill in combination with 821, 841, or 851.)</em></td>
</tr>
<tr>
<td>0835</td>
<td>Support Services</td>
<td>(Home Helper)</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Details</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0841</td>
<td>CAPD/Composite Rate.</td>
<td>Limited to 31 per client, per month. <em>(Do not bill in combination with 821, 831, or 851.)</em></td>
</tr>
<tr>
<td>0845</td>
<td>Support Services (Home Helper)</td>
<td><em>(Home Helper)</em></td>
</tr>
<tr>
<td>0851</td>
<td>Continuous cycling peritoneal dialysis/Composite Rate.</td>
<td>Limited to 31 per client, per month. <em>(Do not bill in combination with 821, 831, or 841.)</em></td>
</tr>
<tr>
<td>0855</td>
<td>Support Services</td>
<td><em>(Home Helper)</em></td>
</tr>
</tbody>
</table>
Authorization

(WAC 182-531-0200)

What is expedited prior authorization (EPA)?

EPA is designed to eliminate the need for written authorization. The agency establishes authorization criteria and identifies the criteria with specific codes, enabling providers to create an EPA number using those codes.

To bill the agency for diagnostic conditions, procedures, and services that meet the EPA criteria, the provider must create a 9-digit EPA number. The first five or six digits of the EPA number must be 87000 or 870000. The last three or four digits must be the code assigned to the diagnostic condition, procedure, or service that meets the EPA criteria. Enter the EPA number on the billing form in the authorization number field, or in the Authorization or Comments section when billing electronically.

The agency denies claims submitted without a required EPA number.

The agency denies claims submitted without the appropriate diagnosis, procedure code, or service as indicated by the last three digits of the EPA number.

The billing provider must document in the client’s file how the EPA criteria were met and make this information available to the agency on request. If the agency determines the documentation does not support the criteria being met, the claim will be denied.

Note: The agency requires written/fax prior authorization when there is no option to create an EPA number.

EPA guidelines

Documentation

The provider must verify medical necessity for the EPA number submitted. The client’s medical record documentation must support the medical necessity and be available upon the agency’s request. If the agency determines the documentation does not support the EPA criteria requirements, the claim will be denied.
EPA Criteria Coding List

A complete EPA number is nine digits. The first five or six digits of the EPA number must be **87000 or 870000**. The last three or four digits must be the code assigned to the diagnostic condition, procedure, or service that meets the EPA criteria.

If the client does not meet the EPA criteria, prior authorization (PA) is required (see Prior Authorization).

<table>
<thead>
<tr>
<th>EPA Code</th>
<th>Service Name</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>870001376</td>
<td>Hemodialysis treatments, more than 14 per month</td>
<td>To be paid for more than 14 in-center hemodialysis treatments per month, the client’s medical records must support the need for additional dialysis treatments as defined by one of the following:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Unable to obtain adequate dialysis as defined by Kt/V &gt; 1.4 with 5 hours three times per week</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Refractory Fluid Overload – successive post dialysis weight increases over three runs or more (minimum 4 hour treatment)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Uncontrolled Hypertension as defined by needing 3 blood pressure medications or more and still having a pre-dialysis BP &gt; 140/90</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Heart failure: class III C or worse (defined by New York Heart Association (NYHA) Functional Classification ) or history of decompensation with HD &lt; 4x per week (decompensation may include increase in edema, dyspnea, increased diuretic therapy, hospitalizations from heart failure)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Unable to complete run - compromised access – termed treatment early (i.e., clotted line), must meet medical necessity.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Pregnancy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Established on &gt;14 runs per month due to one of the above noted reasons (supportive documentation required)</td>
</tr>
</tbody>
</table>

In addition, a signed prescription for additional dialysis by a nephrologist must be in the medical record. The agency requires prior authorization (PA) if the EPA criteria above is not met. The agency may approve more than 14 in-center hemodialysis treatments for up to a 6-month period.
What is a limitation extension (LE)?

An LE is the agency's authorization for the provider to furnish more units of service than are allowed in WAC and agency billing guides. The provider must provide justification that the additional units of service are medically necessary.

LEs do not override the client's eligibility or program limitations. Not all categories of eligibility can receive all services. For example: Kidney dialysis is not covered under the Family Planning Only Program.

Is prior authorization (PA) required for an LE?

Yes. PA is required for an LE.

Note: See the agency's ProviderOne Billing and Resource Guide for more information on requesting authorization.

How do I get LE authorization?

You can obtain an LE by using the written or fax authorization process below.

What is written or fax authorization?

Written or fax authorization is the paper authorization process providers must use when submitting a request for an LE.

How is written or fax authorization requested?

To receive PA or an LE from the agency, providers must complete:

- A General Information for Authorization form, 13-835. This request form MUST be the initial page when you submit your request.

- A Fax/Written Request Basic Information form, 13-756, all the documentation listed on this form, and any other medical justification.

Fax the forms and all documentation to 866-668-1214.
Payment

How does the agency pay for kidney center services?
(WAC 182-540-150)

The agency pays free-standing kidney centers for providing kidney center services to eligible clients using either the:

- **Composite rate payment method** – A payment method in which all standard equipment, supplies, and services are calculated into a blended rate. All in-facility dialysis and all home dialysis treatments are billed under the composite rate method.
  
  ✓ A single dialysis session and related services are paid through a single composite rate payment (see [What is included in the composite rate?](#) for a detailed description on what is required and paid for in a composite rate payment).
  
  ✓ The composite rate is listed in the [Kidney Center Services Fee Schedule](#).

- **Noncomposite rate payment method** – End-Stage Renal Disease (ESRD) services and items covered by the agency, but not included in the composite rate, are billed and paid separately. This methodology uses a maximum allowable fee schedule to pay providers (see [Can services and supplies that are not included in the composite rate be billed separately?](#) for more detail on noncomposite rate payments).

**Note:** The agency recognizes a free-standing kidney center as an outpatient facility.
What is included in the composite rate?  
(WAC 182-540-160)

The composite rate for equipment, supplies, and services for in-facility and home dialysis includes:

- Medically necessary dialysis equipment
- Dialysis services furnished by the facility's staff
- Standard ESRD-related laboratory tests (see Laboratory Services)
- Home dialysis support services including the delivery, installation, and maintenance of equipment
- Purchase and delivery of all necessary dialysis supplies
- Declotting of shunts and any supplies used to declot shunts
- Oxygen used by the client and the administration of oxygen
- Staff time used to administer blood and nonroutine parenteral items
- Non-invasive vascular studies
- Training for self-dialysis and home dialysis helpers

The agency issues a composite rate payment only when all of the above items and services are furnished or available at each dialysis session. If the facility fails to furnish or have available any of the above items, the agency does not pay for any part of the items and services that were furnished.

How many dialysis sessions are included in the composite rate payment?  
(WAC 182-540-150(a)(2) and (3))

The composite rate payment includes the following number of sessions:

<table>
<thead>
<tr>
<th>Limit per session</th>
<th>Revenue code</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 per client, per month</td>
<td>821 and 831</td>
</tr>
<tr>
<td>31 per client, per month</td>
<td>841 and 851</td>
</tr>
</tbody>
</table>

Note: Providers may request a limitation extension (LE) if more sessions than indicated above are medically necessary (see Prior Authorization).
Can services and supplies that are not included in the composite rate be billed separately?  
(WAC 182-540-170)

Supplies and services that are not included in the composite rate may be billed separately when they are:

- Drugs related to treatment, including but not limited to Epoetin Alpha (EPO) and diazepam. The drug must:
  - Be prescribed by a physician
  - Meet the rebate requirements described in WAC 182-530-7500
  - Meet the requirements of WAC 246-905-020 when provided for home use

- Supplies used to administer drugs and blood

- Blood processing fees charged by the blood bank (see [What does the agency pay free-standing kidney centers for?](#))

- Home dialysis helpers

The above items are subject to the restrictions or limitations in this billing guide and applicable WAC.

**Note:** Staff time for the administration of blood is included in the composite rate.
What laboratory services are included in the composite rate?
(\textit{WAC 182-540-180})

- Standard ESRD lab tests are included in the composite rate when performed at recommended intervals.

- The following standard ESRD lab tests, performed by either the facility or an independent laboratory, may be paid outside the composite rate when it is medically necessary to test more frequently. When submitting a claim for tests performed over and above recommended intervals:
  
  ✓ Proof of medical necessity must be documented in the client’s medical record when billing for more frequent testing. A diagnosis of ESRD is not sufficient.

  ✓ The claim must include information on the nature of the illness or injury (diagnosis, complaint, or symptom) requiring the performance of the test(s).

  ✓ (An ICD diagnosis code may be shown in lieu of a narrative description.)

<table>
<thead>
<tr>
<th>Frequency of Testing Under ESRD Composite Rate</th>
<th>Standard ESRD Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Per Treatment</td>
<td>All hematocrit, hemoglobin, and clotting tests</td>
</tr>
<tr>
<td>2. Weekly</td>
<td>Prothrombin time for patients on anticoagulant therapy Serum Creatinine BUN</td>
</tr>
<tr>
<td>3. Monthly</td>
<td>Alkaline Phosphatase Serum Chloride</td>
</tr>
<tr>
<td></td>
<td>CBC Serum Phosphorous</td>
</tr>
<tr>
<td></td>
<td>LDH Serum Potassium</td>
</tr>
<tr>
<td></td>
<td>Serum Albumin SGOT</td>
</tr>
<tr>
<td></td>
<td>Serum Bicarbonate Total Protein</td>
</tr>
<tr>
<td></td>
<td>Serum Calcium</td>
</tr>
</tbody>
</table>

**CAPD Tests:**

<table>
<thead>
<tr>
<th>Albumin</th>
<th>Creatinine</th>
<th>Magnesium</th>
<th>Sodium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkaline</td>
<td>Dialysate Protein</td>
<td>Phosphatase</td>
<td>Total</td>
</tr>
<tr>
<td>BUN</td>
<td>HCT</td>
<td>Phosphate</td>
<td>Protein</td>
</tr>
<tr>
<td>Calcium</td>
<td>HGB</td>
<td>Potassium</td>
<td></td>
</tr>
<tr>
<td>CO2</td>
<td>LDH</td>
<td>SGOT</td>
<td></td>
</tr>
</tbody>
</table>
The following tests are not included in the composite rate and may be billed at the frequency shown without medical documentation. Tests performed more frequently require the appropriate medical diagnosis and medical documentation in the client's medical record. (A diagnosis of ESRD alone is not sufficient.)

<table>
<thead>
<tr>
<th>Frequency of Testing for Separately Billable Tests</th>
<th>Test</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hemodialysis &amp; CCPD Patients</strong></td>
<td></td>
</tr>
<tr>
<td>Once every three months</td>
<td>Serum Aluminum</td>
</tr>
<tr>
<td></td>
<td>Serum Ferritin</td>
</tr>
<tr>
<td>Once every twelve months</td>
<td>Bone Survey (Either the roentgenographic method or the photon absorptiometric procedure for bone mineral analysis.)</td>
</tr>
<tr>
<td></td>
<td>Assay of parathormone (83970)</td>
</tr>
<tr>
<td><strong>CAPD Patients</strong></td>
<td></td>
</tr>
<tr>
<td>Once every three months:</td>
<td>Platelet count</td>
</tr>
<tr>
<td></td>
<td>RBC</td>
</tr>
<tr>
<td></td>
<td>WBC</td>
</tr>
<tr>
<td>Once every six months:</td>
<td>Residual renal function</td>
</tr>
<tr>
<td></td>
<td>24-hour urine volume</td>
</tr>
</tbody>
</table>

- All separately billable ESRD laboratory services must be billed by, and paid to, the laboratory that performs the test.
What does the agency pay free-standing kidney centers for?  
(WAC 182-540-190)

The agency pays free-standing kidney centers for:

- Blood processing and other fees assessed by non-profit blood centers that do not charge for the blood or blood products themselves.
- Costs, up to the agency maximum allowable fee, incurred by the center to administer its in-house blood procurement program.

The agency does not pay free-standing kidney centers for blood or blood products (see WAC 182-550-6500).

Staff time used to administer blood or blood products is included in the payment for the composite rate (see WAC 182-540-150 and 182-540-160).
When does the agency pay for Epoetin Alpha (EPO) therapy?
(WAC 182-540-200(2)(a) and (b))

The agency pays the kidney center for EPO therapy when:

- Administered in the kidney center to a client who meets one of the following:
  - Has a hematocrit less than 33 percent or a hemoglobin less than 11 when therapy is initiated
  - Is continuing EPO therapy with a hematocrit between 30 and 36 percent

- Provided to a home dialysis client when both of the following apply:
  - The client has a hematocrit less than 33% or a hemoglobin less than 11 when therapy is initiated.
  - EPO therapy is permitted by Washington Board of Pharmacy Rules (see WAC 246-905-020 Home dialysis program - legend drugs).

For billing purposes, 100 units of EPO given to the client equals one (1) billing unit. If a fraction of 100 units of EPO is given, round the billing unit as follows:

- If 49 units or less are given, round down to the next 100 units (i.e., bill 31,440 units of EPO as 314 billing units).
- If 50 units or more are given, round up to the next 100 units (i.e., bill 31,550 units of EPO as 316 billing units).
- For agency requirements for billing single dose vials, see the Compliance Packaging section in the agency’s Prescription Drug Program Billing guide.

Where is the fee schedule?

See the agency’s Kidney Center Services Fee Schedule.
Effective for claims billed on and after October 1, 2016
All claims must be submitted electronically to the agency, except under limited circumstances. For more information about this policy change, see Paperless Billing at HCA. For providers approved to bill paper claims, see the agency’s Paper Claim Billing Resource.

What are the general billing requirements?

Providers must follow the agency’s ProviderOne Billing and Resource Guide. These billing requirements include the following:

• Time limits exist for submitting and resubmitting claims and adjustments
• What fee to bill the agency for eligible clients
• When providers may bill a client
• How to bill for services provided to primary care case management (PCCM) clients
• Billing for clients eligible for both Medicare and Medicaid
• Third-party liability claims
• Record-keeping requirements